
|Videos|April 11, 2022
PDE4 Inhibitors and the Treatment Toolbox for AD
Author(s)Miranda Hester
What do topical PDE4 inhibitors bring to the treatment toolbox? Which patients are likely to get the most use out of them? Robert Sidbury, MD, MPH, answers these questions and more in this video interview.
Advertisement
Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, expands on his presentation from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference being held from April 9 to 11 in Baltimore, Maryland.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
2
French Early Access Data on Dupilumab in Pediatric Atopic Dermatitis
3
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
4
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
5


















